 | |
| Clinical data | |
|---|---|
| Other names | N,N-Didesmethyl-4,4'-dihydroxytamoxifen |
| Identifiers | |
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C24H25NO3 |
| Molar mass | 375.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4'-Hydroxynorendoxifen is a synthetic, nonsteroidal antiestrogen of the triphenylethylene group.[1][2] It is a dual selective estrogen receptor modulator (SERM) and aromatase inhibitor (AI), and was derived from tamoxifen, a SERM, and norendoxifen, a metabolite of tamoxifen that has been found to act as an AI.[1][2] The drug has been suggested for potential development as a treatment for estrogen receptor (ER)-positive breast cancer.[1][2] It was synthesized in 2015.[1]
References
- ^ a b c d Lv W, Liu J, Skaar TC, Flockhart DA, Cushman M (March 2015). "Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities". Journal of Medicinal Chemistry. 58 (6): 2623–48. doi:10.1021/jm501218e. PMC 4687028. PMID 25751283.
- ^ a b c Nagini S (2017). "Breast Cancer: Current Molecular Therapeutic Targets and New Players". Anti-Cancer Agents in Medicinal Chemistry. 17 (2): 152–163. doi:10.2174/1871520616666160502122724. PMID 27137076.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 29 December 2022, at 19:23